2018
Acute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry.
Baumbach A, Zaman A, West NEJ, O'Kane P, Egred M, Johnson T, Wheatcroft S, Bowles R, de Belder A, Bouras G, Lansky A, Hill J, Mathur A, de Belder MA, Banning AP. Acute and one-year clinical outcomes following implantation of bioresorbable vascular scaffolds: the ABSORB UK Registry. EuroIntervention 2018, 13: 1554-1560. PMID: 29131802, DOI: 10.4244/eij-d-17-00886.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAcute Coronary SyndromeAdultClinical Decision-MakingCoronary Artery DiseaseCoronary ThrombosisFemaleHumansMaleMiddle AgedPatient SelectionPercutaneous Coronary InterventionPractice Patterns, Physicians'Product Surveillance, PostmarketingProspective StudiesProsthesis DesignRegistriesRisk FactorsTime FactorsTreatment OutcomeUnited KingdomConceptsBioresorbable vascular scaffoldDe novo coronary lesionsOne-year clinical outcomesIndependent clinical events committeeMajor adverse cardiac eventsAbsorb bioresorbable vascular scaffoldCareful implantation techniqueAdverse cardiac eventsNovo coronary lesionsTarget lesion failureAcute coronary syndromeClinical events committeeB2/CCareful patient selectionContemporary drug-eluting stentsDrug-eluting stentsVascular scaffoldsSmall vessel sizeDefinite STCoronary syndromeLesion failureCardiac eventsPatient ageReal-world practiceBVS implantation
2017
Impact of Stent Size Selection on Acute and Long-Term Outcomes After Drug-Eluting Stent Implantation in De Novo Coronary Lesions
Kitahara H, Okada K, Kimura T, Yock PG, Lansky AJ, Popma JJ, Yeung AC, Fitzgerald PJ, Honda Y. Impact of Stent Size Selection on Acute and Long-Term Outcomes After Drug-Eluting Stent Implantation in De Novo Coronary Lesions. Circulation Cardiovascular Interventions 2017, 10: e004795. PMID: 28951394, DOI: 10.1161/circinterventions.116.004795.Peer-Reviewed Original ResearchConceptsDrug-eluting stent implantationReference vessel diameterLong-term outcomesDe novo coronary lesionsNovo coronary lesionsStent implantationDrug-eluting stentsIncomplete stent appositionClinical outcomesCoronary lesionsStent thrombosisStent oversizingStent appositionAngiographic reference vessel diameterSmaller reference vessel diameterGreater stent expansionLesion revascularization rateTarget lesion revascularizationGreater adverse eventsSerial coronary angiographyArterial wall injuryStent size selectionLesion revascularizationRevascularization ratesAdverse events
2015
Safety and efficacy of a novel abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent for the treatment of de novo coronary lesions: Two‐year results from a prospective patient‐level pooled analysis of TARGET trials
Gao Z, Zhang R, Xu B, Yang Y, Ma C, Li H, Chen S, Han Y, Yuan Z, Lansky AJ, Guan C, Leon MB, Gao R, Investigators F. Safety and efficacy of a novel abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent for the treatment of de novo coronary lesions: Two‐year results from a prospective patient‐level pooled analysis of TARGET trials. Catheterization And Cardiovascular Interventions 2015, 85: 734-743. PMID: 25678281, DOI: 10.1002/ccd.25861.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAgedCardiovascular AgentsChinaCoronary Artery DiseaseDrug-Eluting StentsFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPolymersProspective StudiesProsthesis DesignRandomized Controlled Trials as TopicRegistriesRisk FactorsSirolimusTime FactorsTreatment OutcomeConceptsTarget lesion failureFIREHAWK stentStent thrombosisCoronary lesionsMyocardial infarctionNovel abluminal groove-filled biodegradable polymer sirolimus-eluting stentDe novo native coronary lesionsBiodegradable polymer sirolimus-eluting stentsDe novo coronary lesionsPatient-level pooled analysisTarget vessel myocardial infarctionNew drug-eluting stentsNative coronary lesionsNovo coronary lesionsProbable stent thrombosisTarget lesion revascularizationVessel myocardial infarctionSirolimus-eluting stentsPatient-level analysisPatient-level dataLong-term safetyDrug-eluting stentsTwo-year resultsObjective performance criteriaLesion revascularization
2014
TCT-605 Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 2-Year Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials
Zhao Y, Xu B, Yang Y, Zhang R, Changsheng M, Li H, Huo Y, Lansky A, Leon M, Gao R. TCT-605 Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 2-Year Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials. Journal Of The American College Of Cardiology 2014, 64: b176-b177. DOI: 10.1016/j.jacc.2014.07.670.Peer-Reviewed Original Research
2013
TCT-181 Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 12-Month Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials
Gao R, Xu B, Lansky A, Yang Y, Zhang R, Changsheng M, Li H, Chen S, Han Y, Yuan Z, Huo Y, Li W, Zhao Y, Leon M. TCT-181 Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 12-Month Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials. Journal Of The American College Of Cardiology 2013, 62: b59. DOI: 10.1016/j.jacc.2013.08.915.Peer-Reviewed Original ResearchDrug eluting balloons for de novocoronary lesions – a systematic review and meta-analysis
Fröhlich GM, Lansky AJ, Ko DT, Archangelidi O, De Palma R, Timmis A, Meier P. Drug eluting balloons for de novocoronary lesions – a systematic review and meta-analysis. BMC Medicine 2013, 11: 123. PMID: 23657123, PMCID: PMC3648374, DOI: 10.1186/1741-7015-11-123.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsNovo coronary lesionsTarget lesion revascularizationBare metal stentsLate lumen lossDrug-eluting balloonsDe novo coronary lesionsCurrent standard therapyDrug-Eluting BalloonRelative riskCoronary lesionsStent thrombosisMyocardial infarctionStandard therapyStent restenosisSystematic reviewLower late lumen lossAdverse cardiac eventsPooled relative riskRandom-effects modelLesion revascularizationSegment restenosisCardiac eventsComparator treatmentResultsEight studiesA randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
Gao RL, Xu B, Lansky AJ, Yang YJ, Ma CS, Han YL, Chen SL, Li H, Zhang RY, Fu GS, Yuan ZY, Jiang H, Huo Y, Li W, Zhang YJ, Leon MB. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. EuroIntervention 2013, 9: 75-83. PMID: 23685298, DOI: 10.4244/eijv9i1a12.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAgedAnalysis of VarianceAntineoplastic AgentsChinaChi-Square DistributionCoronary AngiographyCoronary Artery DiseaseCoronary RestenosisCoronary StenosisCoronary ThrombosisDrug-Eluting StentsEverolimusFemaleHumansLeast-Squares AnalysisMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPolymersPredictive Value of TestsProspective StudiesProsthesis DesignSirolimusTime FactorsTreatment OutcomeConceptsIschaemia-driven target lesion revascularisationStent late lumen lossTarget vessel myocardial infarctionLate lumen lossTarget lesion failureSingle de novo coronary lesionsDe novo coronary lesionsNovo coronary lesionsCoronary lesionsPrimary endpointCardiac deathI trialNovel abluminal groove-filled biodegradable polymer sirolimus-eluting stentSingle de novo native coronary lesionsDe novo native coronary lesionsBiodegradable polymer sirolimus-eluting stentsNine monthsNative coronary lesionsProbable stent thrombosisTarget lesion revascularisationVessel myocardial infarctionSirolimus-eluting stentsNon-inferiority trialLesion revascularisationEES group
2008
Comparison of Angiographic and Intravascular Ultrasonic Detection of Myocardial Bridging of the Left Anterior Descending Coronary Artery
Tsujita K, Maehara A, Mintz GS, Doi H, Kubo T, Castellanos C, Liu J, Yang J, Oviedo C, Franklin-Bond T, Dasgupta N, Biro S, Dani L, Dangas GD, Mehran R, Kirtane AJ, Lansky AJ, Kreps EM, Collins MB, Stone GW, Moses JW, Leon MB. Comparison of Angiographic and Intravascular Ultrasonic Detection of Myocardial Bridging of the Left Anterior Descending Coronary Artery. The American Journal Of Cardiology 2008, 102: 1608-1613. PMID: 19064013, DOI: 10.1016/j.amjcard.2008.07.054.Peer-Reviewed Original ResearchConceptsMyocardial bridgingIntravascular ultrasoundCoronary arterySystolic compressionLow left ventricular ejection fractionDe novo coronary lesionsLeft ventricular ejection fractionComparison of AngiographicDistal reference segmentsMaximum plaque burdenNovo coronary lesionsVentricular ejection fractionUseful anatomic informationConsecutive patientsEjection fractionLeft anteriorClinical featuresCoronary lesionsPlaque burdenProximal stenosisIntimal thicknessStudy populationPatientsAccurate diagnosisArtery
2007
Cobalt chromium stent with antiproliferative for restenosis trial in India (COSTAR I).
Kaul U, Gupta RK, Mathur A, Dani S, Sapra R, Nayak PR, Lansky A, Cristea E, Carlier S, Gambone L, Litvack F. Cobalt chromium stent with antiproliferative for restenosis trial in India (COSTAR I). Indian Heart Journal 2007, 59: 165-72. PMID: 19122251.Peer-Reviewed Original ResearchConceptsStent late lossGroup 2Group 1Late lossI trialCoronary lesionsGroup 3De novo coronary lesionsSegment late lossBinary restenosis rateNative coronary lesionsNovo coronary lesionsMulti-center registryCoronary stent systemRelease formulationExtended-release formulationSmall-caliber vesselsCobalt-chromium stentNovo lesionsPrimary endpointRestenosis TrialRestenosis rateClinical outcomesFeasibility trialClinical results
2006
The randomised study of the double dose versus single dose sirolimus-eluting stent for the treatment of diabetic patients with de novo coronary lesions.
Costa RA, Sousa JE, Abizaid A, Chaves A, Feres F, Sousa AG, Musumeci G, Mehran R, Fitzgerald PJ, Lansky AJ, Leon MB, Shiran A, Halon DA, Lewis BS, Guagliumi G. The randomised study of the double dose versus single dose sirolimus-eluting stent for the treatment of diabetic patients with de novo coronary lesions. EuroIntervention 2006, 2: 295-301. PMID: 19755304.Peer-Reviewed Original ResearchDe novo coronary lesionsSirolimus-eluting stentsNovo coronary lesionsDiabetic patientsCoronary lesionsDouble doseRevascularisation ratesStent late lumen lossLesion revascularisation rateDouble-blind fashionLate lumen lossBare metal stentsIncomplete stent appositionBinary restenosisPrimary endpointStent thrombosisLumen lossLate thrombosesNeointimal proliferationProcedure successNeointimal volumeNeointimal hyperplasiaPatientsMetal stentsBlind fashionAngiographic Results of the First Human Experience With the Biolimus A9 Drug-Eluting Stent for De Novo Coronary Lesions
Costa RA, Lansky AJ, Abizaid A, Müeller R, Tsuchiya Y, Mori K, Cristea E, Leon MB, Sousa JE, Schmidt T, Hauptmann KE, Grube E. Angiographic Results of the First Human Experience With the Biolimus A9 Drug-Eluting Stent for De Novo Coronary Lesions. The American Journal Of Cardiology 2006, 98: 443-446. PMID: 16893694, DOI: 10.1016/j.amjcard.2006.02.051.Peer-Reviewed Original ResearchConceptsNovo coronary lesionsCoronary lesionsDe novo coronary lesionsNoncomplex coronary lesionsLate lumen lossFirst human experienceDrug-eluting stentsAngiographic characteristicsAngiographic findingsAngiographic resultsLumen lossStent groupBaseline lesionsStent restenosisControl groupLesionsStentsUncoated stentsDistal edgeGroupPatientsHyperplasiaRestenosisEffect of Everolimus-Eluting Stents in Different Vessel Sizes (from the Pooled FUTURE I and II Trials)
Tsuchiya Y, Lansky AJ, Costa RA, Mehran R, Pietras C, Shimada Y, Sonoda S, Cristea E, Negoita M, Dangas GD, Moses JW, Leon MB, Fitzgerald PJ, Müller R, Störger H, Hauptmann KE, Grube E. Effect of Everolimus-Eluting Stents in Different Vessel Sizes (from the Pooled FUTURE I and II Trials). The American Journal Of Cardiology 2006, 98: 464-469. PMID: 16893698, DOI: 10.1016/j.amjcard.2006.02.054.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood Vessel Prosthesis ImplantationCoated Materials, BiocompatibleCoronary AngiographyCoronary RestenosisCoronary VesselsEverolimusFemaleFollow-Up StudiesHumansImmunosuppressive AgentsMaleMiddle AgedProspective StudiesProsthesis DesignSirolimusStentsTreatment OutcomeUltrasonography, InterventionalConceptsBare metal stentsDe novo coronary lesionsNovo coronary lesionsCoronary lesionsNeointimal proliferationStent late lumen lossMid-term outcomesLate lumen lossEverolimus-Eluting StentsQuantitative coronary angiographyMinimum lumen areaVessel sizeII trialCoronary angiographyI trialIncomplete appositionLumen lossStent thrombosisAneurysm formationStent restenosisIntravascular ultrasoundMetal stentsReference diameterLumen areaPatients
2005
Intravascular Ultrasonic Assessment of Stent Diameters Derived from Manufacturer’s Compliance Charts
de Ribamar Costa J, Mintz GS, Carlier SG, Costa RA, Fujii K, Sano K, Kimura M, Lui J, Weisz G, Moussa I, Dangas G, Mehran R, Lansky AJ, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Intravascular Ultrasonic Assessment of Stent Diameters Derived from Manufacturer’s Compliance Charts. The American Journal Of Cardiology 2005, 96: 74-78. PMID: 15979438, DOI: 10.1016/j.amjcard.2005.02.049.Peer-Reviewed Original ResearchConceptsManufacturers' compliance chartsMinimum stent diameterCompliance chartsStent diameterIntravascular ultrasoundStent sizeDe novo coronary lesionsDeployment pressureNovo coronary lesionsMinimal stent diameterHuman coronary arteriesStent manufacturersCoronary lesionsIVUS guidanceCoronary arteryStent lengthInterventional cardiologistsPhysician reportsPercutaneous proceduresStent overlapDifferent stent lengthsStentsBoston ScientificUltrasonic assessmentBare metalAngiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial)
Costa RA, Lansky AJ, Mintz GS, Mehran R, Tsuchiya Y, Negoita M, Gilutz Y, Nikolsky E, Fahy M, Pop R, Cristea E, Carlier S, Dangas G, Stone GW, Leon MB, Müller R, Techen G, Grube E. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). The American Journal Of Cardiology 2005, 95: 113-116. PMID: 15619406, DOI: 10.1016/j.amjcard.2004.08.074.Peer-Reviewed Original ResearchConceptsCoronary lesionsDe novo coronary lesionsStent late lumen lossNoncomplex coronary lesionsSegment diameter stenosisNovo coronary lesionsLate lumen lossEverolimus-eluting stentsFirst human experienceMetallic stent groupEdge restenosisAngiographic characteristicsSegment restenosisAngiographic findingsAngiographic resultsStent thrombosisDiameter stenosisLumen lossStent groupAneurysm formationStent restenosisMetallic stentsRestenosisLesionsStents
2004
High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularizationOne-year results from the SCORE randomized trial
GRUBE E, LANSKY A, HAUPTMANN K, DIMARIO C, DISCIASCIO G, COLOMBO A, SILBER S, STUMPF J, REIFART N, FAJADET J. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularizationOne-year results from the SCORE randomized trial. Journal Of The American College Of Cardiology 2004, 44: 1368-1372. DOI: 10.1016/s0735-1097(04)01351-8.Peer-Reviewed Original ResearchConceptsRestenosis rateStent thrombosisMajor adverse cardiac event ratesAdverse cardiac event ratesDe novo coronary lesionsTarget vessel revascularization rateEnd pointNon-Q-wave MIAngiographic restenosis rateCardiac event rateNovo coronary lesionsPrimary end pointUnacceptable safety profileVessel revascularization rateMyocardial infarction rateOpen-label trialStent thrombosis ratesClinical end pointsOne-year resultsQuantitative coronary angiographyCoronary revascularizationRevascularization ratesInfarction rateCardiac deathCoronary angiographyHigh-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization One-year results from the SCORE randomized trial
Grube E, Lansky A, Hauptmann K, Di Mario C, Di Sciascio G, Colombo A, Silber S, Stumpf J, Reifart N, Fajadet J, Marzocchi A, Schofer J, Dumas P, Hoffmann R, Guagliumi G, Pitney M, Russell M. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization One-year results from the SCORE randomized trial. Journal Of The American College Of Cardiology 2004, 44: 1368-1372. PMID: 15464315, DOI: 10.1016/j.jacc.2004.06.054.Peer-Reviewed Original ResearchConceptsRestenosis rateStent thrombosisMajor adverse cardiac event ratesAdverse cardiac event ratesDe novo coronary lesionsTarget vessel revascularization rateEnd pointNon-Q-wave MIAngiographic restenosis rateCardiac event rateNovo coronary lesionsPrimary end pointUnacceptable safety profileVessel revascularization rateMyocardial infarction rateOpen-label trialStent thrombosis ratesClinical end pointsOne-year resultsQuantitative coronary angiographyCoronary revascularizationRevascularization ratesInfarction rateCardiac deathCoronary angiographySix- and Twelve-Month Results From First Human Experience Using Everolimus-Eluting Stents With Bioabsorbable Polymer
Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ. Six- and Twelve-Month Results From First Human Experience Using Everolimus-Eluting Stents With Bioabsorbable Polymer. Circulation 2004, 109: 2168-2171. PMID: 15123533, DOI: 10.1161/01.cir.0000128850.84227.fd.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsCatheterizationCineangiographyCoated Materials, BiocompatibleComorbidityCoronary AngiographyCoronary RestenosisCoronary StenosisDrug ImplantsEverolimusFemaleFollow-Up StudiesGrowth InhibitorsHumansHyperplasiaImmunosuppressive AgentsLactic AcidMaleMiddle AgedMyocardial InfarctionPolyestersPolymersProspective StudiesSingle-Blind MethodSirolimusStainless SteelStentsTreatment OutcomeTunica IntimaUltrasonography, InterventionalConceptsEverolimus-eluting stentsBare metal stentsRestenosis rateMajor adverse cardiac event ratesAdverse cardiac event ratesDe novo coronary lesionsMajor adverse cardiac eventsPercent neointimal volumeSegment restenosis rateAdverse cardiac eventsCardiac event rateNovo coronary lesionsStent restenosis rateTwelve-month resultsFirst human experienceIntravascular ultrasound analysisInitial clinical experienceLate stent malappositionLate stent thrombosisStent neointimal hyperplasiaSignificant reductionRestenosis reductionCardiac eventsI trialCoronary lesionsNon–Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions
Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, O’Shaughnessy C, Applegate RA, Cannon LA, Mooney M, Farah A, Tannenbaum MA, Yakubov S, Kereiakes DJ, Wong SC, Kaplan B, Cristea E, Stone GW, Leon MB, Knopf WD, O’Neill W. Non–Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions. Circulation 2004, 109: 1948-1954. PMID: 15078794, DOI: 10.1161/01.cir.0000127129.94129.6f.Peer-Reviewed Original ResearchConceptsTarget vessel failureDe novo coronary lesionsNovo coronary lesionsBinary restenosisEnd pointCoronary lesionsMore type C lesionsPrespecified primary end pointPrespecified end pointStent binary restenosisBaseline clinical characteristicsPrimary end pointSecondary end pointsType C lesionsSmooth muscle cell proliferationMulticenter Clinical EvaluationStent late lossTreatment of patientsLarger reference diameterMuscle cell proliferationMicrotubule-stabilizing compoundClinical characteristicsPotent antitumor activityC lesionsClinical evaluation
2003
Benefits of cutting balloon before stenting.
Rizik DG, Popma JP, Leon MB, Mintz GS, Weiner B, Cohen E, Lansky AJ, Adem AM, Bouhasin AP, Wojciechowski C, Weissman NJ. Benefits of cutting balloon before stenting. Journal Of Invasive Cardiology 2003, 15: 624-8. PMID: 14608131.Peer-Reviewed Original ResearchConceptsMinimal stent cross-sectional areaStent cross-sectional areaStent implantationIntravascular ultrasoundCross-sectional areaCulprit coronary artery lesionStent percent diameter stenosisDe novo coronary lesionsSignificant coronary artery diseaseHospital complication ratesNovo coronary lesionsCoronary artery lesionsCoronary artery diseaseCoronary stent implantationAcute luminal gainPercent diameter stenosisQuantitative coronary angiographyArtery lesionsCulprit lesionStent restenosesArtery diseaseComplication rateCoronary angiographyCoronary lesionsBalloon angioplasty
2002
7-Hexanoyltaxol–Eluting Stent for Prevention of Neointimal Growth
Kataoka T, Grube E, Honda Y, Morino Y, Hur SH, Bonneau HN, Colombo A, Di Mario C, Guagliumi G, Hauptmann KE, Pitney MR, Lansky AJ, Stertzer SH, Yock PG, Fitzgerald PJ. 7-Hexanoyltaxol–Eluting Stent for Prevention of Neointimal Growth. Circulation 2002, 106: 1788-1793. PMID: 12356631, DOI: 10.1161/01.cir.0000031734.11420.1c.Peer-Reviewed Original ResearchConceptsBare metal stentsNeointimal growthIntravascular ultrasoundDe novo coronary lesionsAdjacent reference segmentsNovo coronary lesionsIndependent core laboratoryHuman feasibility studyNeointimal tissue growthIVUS substudyUnhealed dissectionConventional mechanical treatmentMulticenter trialCoronary lesionsRestenosis rateAtherosclerotic diseaseIntracoronary brachytherapyIVUS analysisNeointimal responseLong-term benefitsNeointimal thickeningStented segmentsCore laboratoryMetal stentsReference segments